RESUMO
A 20-year-old man with acute B-cell leukemia of Burkitt's type (L3) presenting unusual début symptoms with jaw involvement is reported. The leukemic cells revealed chromosomal abnormalities including four marker chromosomes [1q+, 6q-, t(8;14)].
Assuntos
Cromossomos Humanos 13-15/ultraestrutura , Cromossomos Humanos 6-12 e X/ultraestrutura , Leucemia/genética , Translocação Genética , Adulto , Linfócitos B/ultraestrutura , Medula Óssea/ultraestrutura , Humanos , Cariotipagem , Masculino , TrissomiaAssuntos
Ascite/metabolismo , Fibronectinas/análise , Neoplasias/diagnóstico , Adulto , Idoso , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Neoplasias/análiseRESUMO
Six menstrual cycles and three 1-month periods were studied in seven patients with epilepsy. The patients all had had anti-epileptic treatment for a long time. In each case, the dosages had been costant for at least 1 month prior to the start of the investigation. Blood samples were taken every second day. Phenytoin, phenobarbital, carbamazepine, estradiol and pregesterone were analyzed. The serum levels of the anti-epileptic drugs were correlated to the plasma hormone concentrations. No correlations were obtained between the plasma hormone concentrations and the serum levels of the anti-epileptic drugs. There is, therefore, no evidence that the relationship between the seizure frequency and plasma hormone concentrations, shown in a previous study (Bäckström 1976)) was related to a change in serum levels of the anti-epileptic drugs.
Assuntos
Carbamazepina/sangue , Epilepsia/sangue , Estradiol/sangue , Menstruação , Fenobarbital/sangue , Fenitoína/sangue , Progesterona/sangue , Albumina Sérica , Adulto , Carbamazepina/administração & dosagem , Carbamazepina/uso terapêutico , Epilepsia/tratamento farmacológico , Feminino , Humanos , Fenobarbital/administração & dosagem , Fenobarbital/uso terapêutico , Fenitoína/administração & dosagem , Fenitoína/uso terapêutico , Albumina Sérica/análiseRESUMO
Fifty-eight consecutive patients who were admitted to two departments of general surgery with ascites of unknown origin were investigated by measurement of ascitic fluid fibronectin concentration in a prospective study. A fibronectin concentration of 100 ml/l or more was chosen as indicative of malignant disease. In 40 patients with malignant disease, the median fibronectin concentration was 160 mg/l (interquartile range 120-270, range 20-560). In 18 patients with ascites from benign disease the corresponding figures were 40 mg/l (30-70, 20-90) (p less than 0.01). The diagnostic specificity (predictive value of a positive test) was 1.00 (34/34) (95% confidence interval 0.90 to 1.00), while the diagnostic sensitivity (predictive value of a negative test) was 0.75 (18/24) (95% CI 0.53 to 0.90). In this series an ascitic fluid fibronectin concentration of 100 mg/l or more indicated malignant disease, but a lower value did not exclude it. The test should be investigated in combination with another test with high diagnostic sensitivity to optimise its diagnostic value.